Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b study

Journal:

Nature Medicine

Published:

2025-10-15

DOI:

10.1038/s41591-025-03993-0

Affiliations:

7

Authors:

12

Go to article

Institutions	Authors	Share
AbbVie, United States of America (USA)	7.000000	0.58
Midway Immunology Research Center, United States of America (USA)	1.000000	0.08
Quest Clinical Research, United States of America (USA)	1.000000	0.08
University of Miami (UM), United States of America (USA)	1.000000	0.08
Office of Franco Felizarta, MD, United States of America (USA)	1.000000	0.08
McGill University Health Centre (MUHC), Canada	1.000000	0.08

Interested in Oncology and Carcinogenesis?